financetom
Business
financetom
/
Business
/
Crane maker Manitowoc misses Q2 estimates, sees ending 2025 at lower end of guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Crane maker Manitowoc misses Q2 estimates, sees ending 2025 at lower end of guidance
Aug 7, 2025 2:00 PM

Overview

* Manitowoc Q2 net sales down 4% yr/yr, missing analyst expectations

* Adjusted EPS for Q2 misses estimates, reflecting market challenges

* Company orders rise 6% driven by MGX distribution and European market

Outlook

* Manitowoc expects U.S. crane market to stabilize in six months

* Company anticipates finishing 2025 at lower end of guidance

* Manitowoc sees positive trends in Europe, Middle East, Asia Pacific

* Company adjusts build schedules for second half of 2025

Result Drivers

* MGX DISTRIBUTION - Strong performance in MGX distribution business contributed to a 6% increase in orders, per CEO Aaron Ravenscroft

* EUROPEAN MARKET - Continued momentum in the European tower crane market supported order growth despite tariff challenges

* NON-NEW MACHINE SALES - Non-new machine sales rose 9.7% year-over-year, partially offsetting the decline in overall net sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Miss $539.50 $585 mln

mln (3

Analysts

)

Q2 Miss $0.08 $0.18 (4

Adjusted Analysts

EPS )

Q2 EPS $0.04

Q2 Miss $2.80 $6.54

Adjusted mln mln (3

Net Analysts

Income )

Q2 Net $1.50

Income mln

Q2 Miss $26.30 $35.80

Adjusted mln mln (2

EBITDA Analysts

)

Q2 Gross $99 mln

Profit

Q2 $453.90

Orders mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the heavy machinery & vehicles peer group is "buy."

* Wall Street's median 12-month price target for Manitowoc Company Inc ( MTW ) is $11.00, about 13.4% below its August 6 closing price of $12.47

* The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Booking, Peerspace Launch Partnership Targeting Event Organizers
Booking, Peerspace Launch Partnership Targeting Event Organizers
Mar 13, 2024
09:18 AM EDT, 03/13/2024 (MT Newswires) -- Booking Holdings ( BKNG ) and Peerspace have launched a partnership focusing on event organizers, Peerspace said Wednesday. Event organizers who book a venue on Peerspace and confirmed attendees will get a discount on hotels and rental cars on Booking.com, the company said. The discount is valid for clients in the US, Australia,...
Sector Update: Consumer Stocks Slip Pre-Bell Wednesday
Sector Update: Consumer Stocks Slip Pre-Bell Wednesday
Mar 13, 2024
09:18 AM EDT, 03/13/2024 (MT Newswires) -- Consumer stocks were slipping pre-bell Wednesday with the Consumer Staples Select Sector SPDR Fund (XLP) recently down 0.2% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) declining by 0.3%. Dollar Tree ( DLTR ) was down nearly 14% after it issued fiscal Q1 earnings per share guidance that missed consensus...
Takeda Pharmaceutical Says Mezagitamab Phase 2 Trial Shows 'Positive' Results in Primary Immune Thrombocytopenia Patients
Takeda Pharmaceutical Says Mezagitamab Phase 2 Trial Shows 'Positive' Results in Primary Immune Thrombocytopenia Patients
Mar 13, 2024
09:15 AM EDT, 03/13/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Wednesday that interim analysis from a phase 2 trial of mezagitamab, which is intended for persistent or chronic primary immune thrombocytopenia, showed higher platelet response rates compared with placebo across all three dose cohorts. The company said the trial tested three different doses of subcutaneous mezagitamab against...
AT&T to Buy Carbon Removal Credits from 1PointFive Facility
AT&T to Buy Carbon Removal Credits from 1PointFive Facility
Mar 13, 2024
09:16 AM EDT, 03/13/2024 (MT Newswires) -- AT&T ( T ) has agreed to buy carbon dioxide removal credits from a 1PointFive direct air capture facility that is under construction in Texas, the companies said on Wednesday. The facility is designed to capture up to 500,000 metric tons of carbon dioxide yearly when fully operational, the companies said. The captured...